This phase I/II trial (n=56) will study the safety and side effects of psilocybin in combination with therapy for treating cancer-related anxiety in patients with metastatic cancer. Psilocybin is being studied to treat anxiety or depression in patients with advanced cancer. Participants will receive psilocybin orally and participate in group and individual therapy sessions.
Topic Anxiety
Palliative Care
Compound Psilocybin
Country United States of America
Visit trial
Trial Details
Trial Number
Sponsors & Collaborators
Steven and Alexandra Cohen FoundationIn the bustling neighbourhood of Washington Heights, New York, Alexandra Cohen learned the true value of community and the importance of giving back. From her mother's acts of kindness to the neighbours, she understood that change starts with one person. Today, that core belief drives the Steven & Alexandra Cohen Foundation's philanthropic endeavours across the United States.
Washington University School of Medicine
Located in St. Louis Missouri, researchers at the Washington University School of Medicine have conducted a number of studies with psychedelics inlcuding ketamine, psilocybin and nitrous oxide.
Papers
Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted TherapyThis technical report (2024) describes the evolving guidelines for facilitator use of touch in a group retreat-based format of psilocybin-assisted therapy. The primary goal is to create a safe and supportive haptic experience during sessions, with a secondary goal of maintaining therapeutic boundaries and responding to participant experiences with empathy.